Seres Therapeutics (United States)

A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent<i>Clostridium difficile</i>Infection

Sahil Khanna, Darrell S. Pardi, Colleen Kelly et al. · The Journal of Infectious Diseases · 2016 · 310 citations · Full text

Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial

Elaine W Yu, Liu Gao, Petr Stastka et al. · PLoS Medicine · 2020 · 296 citations · Full text

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After <i>Clostridioides difficile</i> Infection: Lessons Learned From a Phase 2 Trial

Barbara McGovern, Christopher B. Ford, Matthew R. Henn et al. · Clinical Infectious Diseases · 2020 · 150 citations · Full text

IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection

Alyse Frisbee, Mahmoud Saleh, Mary K. Young et al. · Nature Communications · 2019 · 137 citations · Full text

A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis

Matthew R. Henn, Edward J. O’Brien, Liyang Diao et al. · Gastroenterology · 2020 · 102 citations · Full text